Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. by Zalani, Sunita et al.
Proc. Natl. Acad. Sci. USA
Vol. 93, pp. 9194-9199, August 1996
Microbiology
Epstein-Barr viral latency is disrupted by the immediate-early
BRLF1 protein through a cell-specific mechanism
(viral reactivation/BZLF1/Epstein-Barr virus)
SUNITA ZALANI*, ELIZABETH HOLLEY-GUTHRIE*, AND SHANNON KENNEY*t#§
Departments of tMedicine and tMicrobiology and Immunology, and *Lineberger Comprehensive Cancer Center, University of North Carolina,
Chapel Hill, NC 27599
Communicated by Bernard Roizman, The University of Chicago, Chicago, IL, May 10, 1996 (received for review January 31, 1996)
ABSTRACT Epstein-Barr virus (EBV), the causative
agent of infectious mononucleosis, is a human herpesvirus
associated with epithelial cell malignancies (nasopharyngeal
carcinoma) as well as B-cell malignancies. Understanding how
viral latency is disrupted is a central issue in herpesvirus
biology. Epithelial cells are the major site of lytic EBV
replication within the human host, and viral reactivation
occurs in EBV-associated nasopharyngeal carcinomas. It is
known that expression of a single viral immediate-early
protein, BZLF1, is sufficient to initiate the switch from latent
to lytic infection in B cells. Cellular regulation of BZLF1
transcription is therefore thought to play a key role in
regulating the stringency of viral latency. Here we show that,
unexpectedly, expression of another viral immediate-early
protein, BRLF1, can disrupt viral latency in an epithelial
cell-specific fashion. Therefore, the mechanisms leading to
disruption of EBY latency appear to be cell-type specific.
Epstein-Barr virus (EBV) is a human herpesvirus associated
with lymphoid and epithelial cell malignancies (1, 2). A critical
aspect of herpesvirus biology is the maintenance and disrup-
tion of viral latency. EBV infection is generally latent in B cells
but commonly productive in epithelial cells (3-5). EBV reac-
tivation and replication in latently infected B cells can be
activated by treatment with agents such as phorbol 12-
myristate 13-acetate (PMA) or cross-linking of surface immu-
noglobulin (6, 7). These agents activate expression of the
immediate-early (IE) protein, BZLF1 (Z) (8, 9). Z, a tran-
scriptional activator, is a member of the basic leucine zipper
(bZip) family which binds to APi-like Z-response elements in
EBV early promoters (10-12). Expression of transfected Z in
latently infected lymphocytes is sufficient to trigger the lytic
cycle (13-15).
In addition to Z, EBV has one other IE protein, BRLF1 (R).
Like Z, R is a transcriptional activator and sequence-specific
DNA-binding protein (16-22). A number of early EBV pro-
moters contain upstream R binding sites (a G+C-rich motif)
and are transcriptionally activated by R in transient transfec-
tion assays. Certain early viral promoters require both Z and
R for maximal transcriptional activation (13, 19, 21). In
contrast to Z, expression of transfected R in EBV-infected B
cells does not disrupt latency (19).
The finding that expression of Z is sufficient to disrupt viral
latency has led to a model in which lytic EBV infection results
from activation of BZLF1 transcription by cellular transcrip-
tion factors (23). The Z protein can potentially be derived from
two different promoters, Zp and Rp (16) (Fig. 1). The more
proximal promoter, Zp (from which most, if not all, Z protein
is derived), directs transcription of a 1.0-kb message encoding
the Z protein alone. The distal promoter, Rp, directs tran-
scription of a 2.8-kb message encoding the R protein, and
potentially the Z protein as well (if the message can be
bicistronically translated) (16). Zp and Rp are normally inac-
tive in latently infected cells, but agents that disrupt viral
latency such as PMA and anti-immunoglobulin activate ex-
pression of Zp, as well as Rp (8, 9), with similar kinetics.
Although the phenotype of virus lacking Z or R has not been
reported, it is likely that both Z and R are required for
disruption of viral latency. Assuming that this is the case,
transfected Z may activate Rp in latently infected B cells, and
the resultant combination of Z and R then leads to disruption
of viral latency. In contrast, transfected R may be incapable of
activating Zp within the endogenous viral genome. The effects
of Z and R upon Zp and Rp transcription have not been
carefully studied except in transient reporter assays. In these
types of experiments, Z has been reported to activate its own
promoter (Zp) (24) as well as the R promoter (Rp) (25), and
R has been shown to activate Rp at a low level through an
apparently non-binding mechanism (25, 26). The effect ofR on
Zp expression has not been reported.
In this paper, we demonstrate that expression of the R IE
protein is sufficient to disrupt viral latency in an epithelial
cell-specific manner. This ability of R to induce lytic viral
infection in epithelial cells, but not lymphoid cells, correlates
with its ability to activate Zp and Rp expression from the
endogenous viral genome only in epithelial cells. Furthermore,
we demonstrate that in contrast to the results of plasmid-based
reporter assays, transfected Z primarily activates Rp in the
endogenous viral genome, rather than Zp. These results
suggest that in epithelial cells (the major site of lytic EBV
infection in vivo), cellular transcription factors which activate
Rp may initiate the disruption of viral latency.
MATERIALS AND METHODS
Cell Lines. P3HR1, Raji, and Akata (7) are EBV-positive
Burkitt lymphoma cell lines. SFC4 and CB/95 are human
B-cell lines immortalized with EBV. NPC-KT is an EBV-
positive epithelial cell line derived from the fusion of a human
adenoidal epithelial cell line and a primary EBV-positive
nasopharyngeal carcinoma (27). The epithelial D98/HE-R-1
cell line was formed by fusion of a HeLa cell subclone (D98)
with the EBV-positive Burkitt lymphoma cell line P3HR/1
(28). All lymnphoid cell lines were maintained in RPMI 1640
medium supplemented with 10% fetal calf serum. Epithelial
cell lines were maintained in Dulbecco's modified Eagle's
medium H supplemented with 10% fetal calf serum.
EBV Plasmids. The BMLF1 promoter plasmid contains the
early EBV promoter sequences from -331 to + 1 linked to the
Abbreviations: EBV, Epstein-Barr virus; Z, BZLF1 gene product; R,
BRLF1 gene product; Zp, BZLF1 promoter; Rp, BRLF1 promoter;
CAT, chloramphenicol acetyltransferase; IE, immediate-early; PMA,
phorbol 12-myristate 13-acetate; CMV, cytomegalovirus, IUdR, io-
dodeoxyuridine.
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to yield a 156-bp antisense riboprobe spanning the Zp initia-
tion site. Total RNA (15-20 ,ug) was hybridized with 20,000
cpm of riboprobe at 50°C for 16 h and then digested with 3
units of RNase One at room temperature for 1 h. Samples were
denatured and fragments were resolved by electrophoresis
through an 8 M urea/polyacrylamide gel. Hybridization to Zp-
and Rp-initiated transcripts yields protected species of 115 and
148 bp, respectively. The radiolabeled actin riboprobe was
generated by in vitro transcription using the actin control
plasmid (Promega).
FIG. 1. The position of the two promoters driving Z and R
transcription (Zp and Rp) is shown below the genomic map. The size
of the messages arising from these promoters is shown.
heterologous reporter gene, chloramphenicol acetyltrans-
ferase (CAT), in the pCAT3M vector as described (22).
The CMV-Z plasmid has the BZLF1 cDNA under the
control of the cytomegalovirus (CMV) promoter in the
pHD1013 vector as described (22). The two BRLF1 expression
vectors, one containing the BRLF1 gene under the control of
CMV promoter (21) and another containing the BRLF1 gene
under the control of the simian virus 40 promoter (29), have
been described. The plasmid pRZSphHind contains the Hin-
dIII-SphI fragment (spanning the EBV sequences from -235
to + 115 relative to the BZLF1 mRNA start site) inserted into
the Hincll site of the pBS+ plasmid (Stratagene). This plasmid
was used to generate a riboprobe for RNase protection assays.
DNA Transfection. Plasmid DNA was purified through
either Qiagen columns as described by the manufacturer
(Qiagen, Chatsworth, CA) or double-banded cesium chloride.
DNA (5 ,ug) was transfected into cells by electroporation with
a Zapper electroporation unit (Medical Electronics Shop,
University of Wisconsin) at 1500 V as described (22). Epithe-
lial cells were suspended into RPMI 1640 medium before
electroporation.
CAT Assays. Cell extracts were prepared 48 h after trans-
fection and incubated at 37°C with [14C]chloramphenicol in
the presence of acetyl coenzyme A as described (30). The
percent acetylation of chloramphenicol was quantitated by
thin layer chromatography followed by Phosphorlmager
screening or by scintillation counting.
Immunoblot Analysis. Immunoblot analysis was performed
for the detection of the EBV Z and BMRF1 proteins as
described (31). The Z monoclonal antibody BZ.1 (diluted 1:50)
(a gift from Alan Rickinson, University of Birmingham Med-
ical School, Birmingham, U.K.) was used to detect Z expres-
sion and the monoclonal antibody 9240 (diluted 1:40) (Cap-
ricorn) was used to detect induction ofBMRF1 (early antigen-
diffuse). Proteins were visualized by the chemiluminescence
method after immunoblotting (Amersham).
EBV Termini Analysis. Latently infected cells were trans-
fected with either pHD1013 vector DNA, the BZLF1 expres-
sion vector, or the BRLF1 expression vector. Total cellular
DNA was prepared 48 h after transfection. The DNA was cut
with BamHI, run on an agarose gel, and transferred to
nitrocellulose. The blot was probed with a 32P-labeled ribo-
probe spanning the EBV sequences in the 1.9-kb XhoI frag-
ment as described (32).
RNase Protection Assays. Total cellular RNA was isolated
using the Trizol reagent (GIBCO/BRL) 24 h after transfection
with the pHD1013 vector, the BZLF1 expression vector, or the
BRLF1 expression vector, or 20 h after treatment of NPC-KT
cells with PMA (20 ng/ml) and iododeoxyuridine (IUdR) (75
,ug/ml), or 4 h after treatment of Akata cells with anti-human
IgG (100 ,ug/ml). RNase protection was performed using the
RNase protection assay system (Promega) as described by the
manufacturer. The plasmid pRZSphHind was cut with Dral
(-34 relative to the BZLF1 mRNA start site) and transcribed
using T3 RNA polymerase in the presence of 32P-labeled UTP
RESULTS
R Activates Early Gene Expression in Epithelial Cells But
Not Lymphoid Cells. To compare the ability of R versus Z to
induce lytic viral infection in different cell types, we trans-
fected the R or Z gene products (under the control of a strong
constitutive promoter) into various types of latently infected
cells. Induction of the EBV lytic cycle was monitored by the
appearance of an early viral protein, BMRF1 (early antigen-
diffuse), which is not expressed in latently infected cells. As
shown for the Raji EBV-infected Burkitt lymphocyte line in
Fig. 2a, expression of the Z gene product, as expected, induced
early antigen expression. In Burkitt cells, expression of the R
protein did not activate early antigen expression. Likewise, as




















FIG. 2. Five micrograms ofpHD1013 vector DNA (a gift from E. S.
Huang, University of North Carolina, Chapel Hill), the BZLF1
expression plasmid (containing the BZLF1 gene linked to the CMV IE
promoter), or the BRLF1 expression construct (containing the
BRLF1 gene under the control of the CMV IE promoter) were
transfected into cells. The cell lines used included a latently infected
Burkitt B-cell line (Raji) (A), a primary B cell line immortalized with
EBV (CB/95) (B), or two latently infected epithelial cell lines,
NPC-KT (C) and D98/HE-R-1 (D). Immunoblot analysis was per-
formed using the monoclonal antibody BZ.1 (diluted 1:50) (a gift from
Alan Rickinson) to detect the presence of Z, and the monoclonal
antibody 9240 (diluted 1:40) (Capricorn) to detect the expression of
early antigen-diffuse (EAD). Similar results as shown inA and B were
obtained with another Burkitt cell line, P3HR1, and another lympho-
blastoid cell line, SFC4 (data not shown).
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(Fig. 2b), expression of Z, but not R, induced early antigen
expression, although in these cells Z was considerably less
efficient in disrupting viral latency than in the Burkitt lines.
In contrast, expression of either R or Z induced early viral
protein expression in two different EBV-infected epithelial
cell lines (Fig. 2 c and d). Given that lytic viral infection likely
requires the presence of Z, as well as R, the ability of
transfected R to induce Z expression in epithelial cells (from
the endogenous viral genome) was assessed by immunoblot
analysis using a monoclonal antibody specific to the Z protein.
As shown in Fig. 2 c and d, epithelial cells transfected with R
also expressed the IE protein Z, indicating that R can activate
Z expression in this cell type. Similar results were obtained
using a BRLF1 expression vector driven by the simian virus 40
promoter. Thus, expression of R is sufficient to activate the
lytic viral cascade in epithelial cells but not lymphoid cells.
R Induces Lytic EBV Replication in Epithelial Cells. The
previous results indicate that R can activate expression of at
least two lytic EBV genes (BZLF1 and BMRF1) in epithelial
cells. However, many different EBV genes are required for
lytic replication, and therefore the early gene expression
induced by R in epithelial cells might be abortive and not
support successful viral replication. To compare the ability of
Z versus R to induce lytic viral replication in epithelial cells,
we performed Southern blot analyses to distinguish latent
(episomal) versus lytic (linear) EBV genomes as described (32).
As shown in Fig. 3, expression of Z, as expected, resulted in
conversion of the virus from the episomal to the linear form
in both lymphoid cells (data not shown) or epithelial cells.
Consistent with the immunoblot analysis, expression of R also
induced lytic replication of the EBV genome in epithelial cells.
These results indicate that R is able to induce full lytic infection
in epithelial cells, not simply abortive expression of viral early
proteins.
R Induces Zp and Rp Transcription in Epithelial Cells But











FIG. 3. Latently infected NPC-KT (A) and D98/HE-R-1 (B) cells
were transfected with 5 ,g of pHD1013 vector DNA, 5 ,ug of the
BZLF1 expression vector, or 5 ,ug of the BRLF1 vector DNA. The
cellular DNA was isolated 48 h after transfection, cut with the
restriction enzyme BamHI, and analyzed by Southern blot using a
32P-labeled riboprobe spanning the 1.9-kbXhloI sequence ofEBV. This
assay (32) distinguishes between fused versus unfused viral termini.
The latent (episomal) virus contains only fused termini, whereas lytic
replication results in an increased number of fused termini (due to
replicative intermediates) as well as the appearance of unfused termini
(due to the replicated linear form).
reactivation (23), the activation of Zp transcription by cellular
factors is the initial event leading to disruption of viral latency.
In this model, the Z protein then activates Rp, as well as further
activating Zp. The combined transactivator functions of Z and
R then lead to an irreversible activation of the lytic cascade.
However, the effects of transfected Z and R upon Zp and Rp
expression within the endogenous viral genome have not been
well studied.
Using an RNase protection assay, we examined the effects
of transfected R and Z upon Zp and Rp expression in different
cell types. The 1.0-kb BZLF1 RNA (arising from Zp) and
2.8-kb BRLF1 plus BZLF1 RNA (arising from Rp) were
detected using an RNA probe as shown in Fig. 4a. Disruption
of viral latency induced by either cross-linking of surface
immunoglobulin (Akata cells) or PMA/IUdR treatment
(D98/HE-R-1 and NPC-KT.cells) activated Zp, as well as Rp,
expression in each cell type (Fig. 4b). Similar results were
obtained using PMA to disrupt viral latency in either Raji or
Akata cells (data not shown).
In contrast to the effects of immunoglobulin cross-linking
and PMA, transfected Z primarily activated Rp (with little, if
any, Zp transcription observed) in both the Raji B-cell line
(Fig. 4c) and the epithelial D98/HE-R-1 cell line (Fig. 4d).
This result is in conflict with the results of plasmid-based
reporter gene assays, in which Z can activate its own promoter
(24). Transfected R did not activate either Zp or Rp in the Raji
cell line (Fig. 4c), consistent with the inability of R to disrupt
viral latency in these cells. In contrast to the results seen in
Burkitt cells, R activated both Zp and Rp in the epithelial
D98/HE-R-1 cell line (Fig. 4d). Similar results were obtained
in the epithelial NPC-KT cell line (data not shown). Thus, the
ability of transfected R to disrupt viral latency in epithelial
cells, but not lymphoid cells, correlates with its ability to
activate Zp and Rp transcription from the endogenous viral
genome in an epithelial cell-specific manner.
The R Transactivator Function Is Not Cell Type-Specific in
Plasmid-Based Reporter Assays. To determine if R transac-
tivator function is impaired in B cells, we performed plasmid-
based reporter gene assays using an early EBV promoter
construct previously shown to be directly bound and transcrip-
tionally activated by R (20, 22). These results indicate that the
transcriptional activator function of transfected R in plasmid-
based assays is similar in B cells and epithelial cells (Fig. 5).
Therefore, the inability of transfected R to activate viral
replication in B cells does not appear to be due to the absence
of an essential trans-acting factor required for R transactivator
function in B cells.
DISCUSSION
This report demonstrates that the EBV IE protein, R, can
disrupt viral latency in an epithelial cell-specific fashion.
Previous studies of EBV reactivation have examined the
mechanisms by which viral latency is disrupted in B cells, and
have identified the Z IE protein as the critical initiator of this
process. However, since lytic EBV replication in vivo occurs
primarily in epithelial cells, rather than B cells, induction of
lytic viral replication by R may be an equally important
mechanism for disrupting viral latency in the human host.
The ability of transfected R to disrupt viral latency in
epithelial cells, but not B cells, correlates with its ability to
induce expression of the Zp and Rp promoters only in
epithelial cells. R is a transcriptional activator which binds to
specific G+C-rich motifs present in many early EBV promot-
ers. The finding that R activates expression of both Zp and Rp
in the endogenous genome is somewhat surprising, given that
neither of these promoters is thought to contain R binding sites
(18, 26). However, we (and others) have previously shown that
R binding sites can function from a distance as enhancer
elements (19, 20, 22), and more than 300 putative R binding
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FIG. 4. (a) RNase protection assays were performed using a single-strand 32P-labeled riboprobe. Hybridization of the probe to Zp- and
Rp-derived mRNA results in protected fragments of 115 and 148 bp, respectively. The transfected BZLF1 vector yields an 80-bp protected fragment
(not shown). (b) Total cellular RNA was isolated from Akata Burkitt cells [either untreated or treated with anti-human IgG (100 ,g/ml) for 4
h], NPC-KT cells [either untreated or treated with PMA (TPA; 20 ng/ml) and IUdR (75 Ag/ml) for 20 h], and D98/HE-R-1 cells (either untreated
or treated with PMA and IUdR for 20 hours). The RNA was hybridized to the 32P-labeled riboprobe, digested with RNase (Promega RNase
protection assay system), denatured, and run on a 6% sequencing gel. The expected size of the Zp- and Rp-derived protected fragments is shown.
(c) Raji cells were transfected with 5 jig of pHD1013 vector DNA, 5 ,ug of the BZLF1 expression vector, or 5 ,ug of the BRLF1 expression vector
DNA. Total RNA was isolated and examined in RNase protection assays. The corresponding actin mRNA for each condition is shown in the panel
below. (d) D98/HE-R-1 cells were transfected with vector DNA, the BZLF1 expression vector, or the BRLF1 expression vector and processed for
RNase protection assays as described above.
sites have been located in the EBV genome (18). It thus
remains possible that distant R binding sites (not contained
within the previously studied Zp and Rp reporter constructs)
mediate R-induced activation of Zp and Rp within the context
of the viral genome. Assuming this is the case, then the Rp and
Zp promoters are presumably less accessible to direct binding
by R in B cells. Cell-specific differences in the methylation
state of the Zp and Rp promoters, or differences in the
chromatin configuration around these promoters, might ex-
clude R binding in B cells, while allowing such binding in
epithelial cells.
Alternatively, as we have previously suggested (26), R may
activate certain promoters through a nonbinding mechanism.
If the R-induced activation of Zp and Rp is mediated through
this novel mechanism, then the trans-acting cellular factors
required for this process may be more available in epithelial
cells than in B cells. The domains of R essential for transac-
tivator function have been shown to be cell-type dependent
(33), suggesting that R-induced transactivation may be medi-
ated by different mechanisms in different cell types.
Another group has previously reported that R expressed in
vaccinia virus can activate early gene expression in lympho-
blastoid cell lines, but not Burkitt cells (34). This group did not
define whether the R vaccinia virus induced abortive lytic
infection (limited to early gene expression) or progressed to
full viral replication. However, our results here clearly indicate
that transfected R alone (in contrast to Z) cannot disrupt viral
latency in lymphoblastoid cells. It remains possible that a
vaccinia virus-encoded protein allows R to perform this
function in B cells.
It has been previously reported that the Z gene product can
activate expression of Zp in transient transfection assays (24).
Based on the results of such assays, a model for EBV reacti-
vation has been proposed (23) in which Zp is initially activated
by cellular transcription factors, followed by autoactivation of
Zp by its own gene product, and Z-induced activation of Rp.
The precise cellular transcription factors initially activating Zp
have yet to be defined, although both CREB and AP1 have
been suggested (35, 36).
The results here indicate that transfected Z primarily acti-
vates Rp, rather than Zp, in the endogenous genome. Another
group has recently reported a similar result (37). Therefore,
the results of transient plasmid-based assays may not reflect
the sequence of events in the actual genome. Instead, as shown
in Fig. 6 (model 1), our data suggest that in B cells, activation
of Zp by cellular transcription factors leads to subsequent
activation of Rp, rather than Zp. The combination of the Z and
R transcription factors would then lead to maximal induction
of early EBV promoters (13, 19, 21).
From the results presented here, we now propose an additional
mechanism for disruption of viral latency in epithelial cells. This
pathwaywould be initiated by cellular transcription factors known
to activate Rp (such as Zif268 and Spl) (26, 31), rather than Zp.
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FIG. 5. D98/HE-R-1 and Raji cells were transfected with 5 ,ug of
the BMLF1 promoter plasmid (containing the BMLF1 early EBV
promoter linked to the CAT reporter gene) and 5 ,ug of either the
pHD1013 vector or the BRLF1 expression vector. CAT assays were
performed as described (30). The average fold activation after co-
transfection with the BRLF1 expression vector versus the control
vector is shown.
Rp, as well as Zp. As in B cells, the combination ofR and Zwould
subsequently induce maximal activation of early viral promoters.
It remains possible that simultaneous activation of Zp and Rp
occurs in some circumstances.
The transmission of herpesviruses from host to host requires
that viral latency be disrupted. We have demonstrated here a
novel mechanism for disruption of EBV latency in epithelial
cells in vitro. Given the rather unusual histories of our two
EBV-infected epithelial cell lines (both being derived from
fusions of an EBV-infected cell with an epithelial cell), it will
be important to confirm our results with additional studies
before concluding that our results are relevent to EBV-
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FIG. 6. Shown is a schematic representation of models for disrup-
tion of viral latency. Model 1 (B cells and epithelial cells): Cellular
factors initially activate Zp, leading to the production of Z. Z
subsequently activates Rp, leading to production of R. Z and R can
synergistically activate early viral promoters leading to disruption of
viral latency. Model 2 (epithelial cells only): Cellular factors initially
activate Rp rather than Zp. The R protein subsequently activates its
own promoter as well as Zp. Z and R then synergistically activate early
viral promoters, as in model 1.
infected epithelial cells in vivo. Nevertheless, since the major
site of lytic EBV replication in the human host is thought to be
within epithelial cells rather than B cells (2), this newly
recognized pathway for viral reactivation may in fact play a
critical role in vivo for transmission of virus. The identification
of the specific cellular factors that disrupt viral latency will
ultimately be required for a full understanding of this key
aspect of herpesvirus biology. Our results presented here
suggest that cellular factors that activate Rp, as well as Zp, may
mediate disruption of viral latency in epithelial cells.
We thank Joseph Pagano and Albert Baldwin for critical reading of
the manuscript and Rachel Elizabeth Edwards for help with the viral
replication assay. This work was supported by Grants R01CA58853
and KO4CA01711 from the National Institutes of Health.
1. Kieff, E. & Leibowitz, D. (1990) in Virology, eds. Fields, B. N.,
Knipe, D., Chanock, R. M., Hirsch, M. S., Melnick, J. L.,
Monath, T. P. & Roizman, B. (Raven, New York), pp. 1889-
1920.
2. Miller, G. (1990) in Virology, eds. Fields, B. N., Knipe, D.,
Chanock, R. M., Hirsch, M. S., Melnick, J. L., Monath, T. P. &
Roizman, B. (Raven, New York), pp. 1921-1957.
3. Martel-Renoir, D., Grunewald, V., Touitou, R., Schwaab, G. &
Joab, I. (1995) J. Gen. Virol. 76, 1401-1408.
4. Sixbey, J. W., Nedrud, J. G., Raab-Traub, N., Hanes, R. A. &
Pagano, J. S. (1984) N. Engl. J. Med. 310, 1225-1230.
5. Li, Q. X., Young, L. S., Niedobitek, G., Dawson, C. W., Birken-
bach, M., Wang, F. & Rickinson, A. B. (1992) Nature (London)
356, 347-350.
6. Zur Hausen, H., Bornkamm, G., Schmidt, R. & Hecker, E. (1979)
Proc. Natl. Acad. Sci. USA 76, 782-785.
7. Takada, K. & Ono, Y. (1989) J. Virol. 63, 445-449.
8. Flemington, E., Goldfield, A. & Speck, S. (1991) J. Virol. 65,
7073-7077.
9. Laux, G., Freese, U., Fischer, R., Polack, A., Kofler, E. &
Bornkamm, G. (1988) Virology 162, 503-507.
10. Chang, Y., Dong, D., Hayward, G. & Hayward, SD (1990)J. Virol.
64, 3358-3369.
11. Farrell, P., Rowe, D., Rooney, C. & Kouzarides, T. (1989)EMBO
J. 8, 127-132.
12. Flemington, E. & Speck, S. (1990) Proc. Natl. Acad. Sci. USA 87,
9459-9463.
13. Chevallier-Greco, A., Manet, E., Chavrier, P., Mosnier, C.,
Daillie, J. & Sergeant, A. (1986) EMBO J. 5, 3243-3249.
14. Countryman, J. & Miller, G. (1985) Proc. Natl. Acad. Sci. USA
82, 4085-4089.
15. Takada, K., Shimuzu, N., Sakuma, S. & Keating, A. (1986)
J. Virol. 57, 1011-1022.
16. Manet, E., Gruffat, H., Trescol-Biemont, M. C., Moreno, I.,
Chambard, P., Giot, J. F. & Sergeant, A. (1989) EMBO J. 8,
1819-1826.
17. Hardwick, J. M., Lazarowits, S. & Hayward, S. (1988) J. Virol. 62,
2274-2284.
18. Gruffat, H. & Sergeant, A. (1994) Nucleic Acids Res. 22, 1172-
1178.
19. Cox, M., Leahy, J. & Hardwick, J. (1990) J. Virol. 64, 313-321.
20. Gruffat, H., Duran, N., Buisson, M., Wild, F., Buckland, R. &
Sergeant, A. (1992) J. Virol. 66, 46-52.
21. Quinlivan, E., Holley-Guthrie, E., Norris, M., Gutsch, D.,
Bachenheimer, S. & Kenney, S. (1993) Nucleic Acids Res. 21,
1999-2007. -
22. Kenney, S., Holley-Guthrie, E., Mar, E. & Smith, M. (1989)
J. Virol. 63, 3878-3883.
23. Garcia-Blanco, M. & Cullen, B. (1991) Science 254, 815-820.
24. Flemington, E. & Speck, S. (1990) J. Virol. 64, 1227-1232.
25. Sinclair, A. J., Brimmel, M., Shanahan, F. & Farell, P. J. (1991)
J. Virol. 65, 2237-2244.
26. Zalani, S., Holley-Guthrie, E., Gutsch, D. & Kenney, S. (1992)
J. Virol. 66, 7282-7292.
27. Takimoto, T., Kamide, M. & Umeda, R. (1984) Arch. Otorhino-
laryngol. 239, 87-92.
28. Glaser, R. & O'Neill, F. J. (1972) Science 176, 1245-1247.
9198 Microbiology: Zalani et aL
Microbiology: Zalani et al.
29. Chevallier-Greco, A., Gruffat, H., Manet, E., Calender, A. &
Sergeant, A. (1989) J. Virol. 63, 615-623.
30. Gorman, C. M., Moffat, L. F. & Howard, B. H. (1982) Mol. Cell.
Biol. 2, 1044-1051.
31. Zalani, S., Holley-Guthrie, E. & Kenney, S. (1995) J. Virol. 69,
3816-3823.
32. Sato, H., Takimoto, T., Tanaka, S., Yanaka, J. & Raab-Traub, N.
(1990) J. Virol. 64, 5295-5300.
Proc. Natl. Acad. Sci. USA 93 (1996) 9199
33. Hardwick, J. M., Tse, L., Applegren, N., Nicholas, J. & Veliuona,
M. A. (1992) J. Virol. 66, 5500-5508.
34. Bogedain, C., Alliger, P., Schwarzmann, F., Marschall, M., Wolf,
H. & Jilg, W. (1994) J. Virol. 68, 1200-1203.
35. Ruf, I. K. & Rawlins, D. R. (1995) J. Virol. 69, 7648-7657.
36. Flemington, E. & Speck, S. (1990) J. Virol. 64, 1217-1226.
37. Kolman, J. L., Taylor, N., Gradoville, L., Countryman, J. &
Miller, G. (1996) J. Virol. 70, 1493-1504.
